Roche has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) to market Tamiflu (oseltamivir phosphate) capsules in pediatric doses of 30 mg and 45 mg. Tamiflu, which is indicated for the prevention and treatment of influenza types A and B in patients one year and older, is currently available in a 75 mg capsule for adults as well as liquid suspension formulation for children.
A new study finds that while “expert centers” with extensive experience in managing cancer have higher overall costs, the approach is more cost-effective over time than referring patients to a less experienced medical center.
Human embryonic stem cells (hESCs) hold great promise forbenefiting degenerative diseases, and do so by invoking multiplemechanisms. Such cells can be grown in a manner compatible with clinicaluse (i.e., without animal feeder layers) and even without the need forimmunosuppression.
There is no evidence that walk-in centers shorten waiting times to see a general practitioner, say researchers in a BMJ study published online today.
A new study led by researchers at Warwick Medical School at the University of Warwick reveals that patients using cholesterol busting statins get a bonus benefit from such drugs as the Warwick researchers have now found that statins also have a positive effect on blood pressure levels.
Researchers from Harvard Medical School, Boston, have found that most individuals with acute myeloid leukemia (AML) inappropriately express a protein known as CDX2 in their leukemic cells.
The Prostate Cancer Foundation (PCF) announced today that John A. Martignetti, of Mount Sinai School of Medicine’s Department of Genetics And Genomic Sciences, is a recipient of one of the 2006 Competitive Awards Program grants. Sixty-three research investigators from four countries received a total of $6.1 million in awards.
Cancer Treatment Centers of America announced today its plans to launch a new cancer vaccine therapy that expands treatment options for thousands of women with advanced stage ovarian cancer. This innovative treatment will be offered by Cancer Treatment Centers of America and developed by AVAX Technologies, Inc. (OTCMarket: AVXT.OB).
It is well known that cancer patients undergoing chemotherapy and radiation therapy often experience nausea and loss of appetite. But until now, few researchers have looked into why this happens and what can be done to ensure that cancer patients maintain a healthy diet during treatment.
Researchers at the University of Pennsylvania Schools of Medicine and Veterinary Medicine have determined a way to pre-screen cancer patients to see if they are suitable candidates for proteasome inhibitors, a promising class of anti-cancer drugs.